Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation

DOI: 10.1080/2162402X.2016.1139274

Keywords: Adoptive cellular immunotherapy, donor lymphocyte infusion, EBV, EBV-CTL, hematopoietic stem cell transplantation, PTLD, rituximab, relapse

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text